HealthTab™ Systems Deployed in Select Shoppers Drug Mart® Locations, Patient Testing Begins
August 10 2021 - 4:00AM
AVRICORE HEALTH INC. (TSXV: AVCR) (the
"
Company" or “
AVCR”) announces
that patient testing has begun on the HealthTab™ platform in select
Shoppers Drug Mart® pharmacies.
The participating Shoppers Drug Mart® pharmacies have now
received their HealthTab™ systems and will begin offering screening
tests to patients with known conditions associated with
pre-diabetes, or already identified as diabetic, to provide
diagnostic support and pharmacist-led consultation services.
"We are very excited to pilot Point of Care Testing with
HealthTab and the Afinion 2 analyzer at select Shoppers Drug Mart®
pharmacies,” said Frank Hack, Director of Complex Care at Shoppers
Drug Mart. “We are committed to improving access to care through
our pharmacy network and enabling our pharmacists to drive improved
patient outcomes by providing value added patient care
services."
In May 2021, Avricore signed a Master Agreement with Shoppers
Drug Mart Inc. to pilot the HealthTab™ platform. This agreement
allows patients access to point-of-care blood screening and
health-data management for potential risks for developing diabetes
and cardiovascular conditions through the HealthTab™-integrated
Afinion 2™ analyzers by Abbott Rapid Diagnostics.
The program initially announced 11 locations, however, the
Master Agreement has since been updated to 15 locations.
Beta-testing at an initial store proved extremely successful, with
more than 90 patients tested and over 600 results reported over the
initial trial period. The program’s primary focus is to screen
patients at-risk for diabetes and cardiovascular disease.
“We could not be happier with the collaborative and progressive
approach taken in this project with Shoppers Drug Mart,” said
Hector Bremner, Avricore Health CEO. “We are really excited to see
the first patients’ feedback and ensuring they have the very best
experience.”
In-store signage and print material will let customers know they
are able to request HealthTab™ tests, and existing patients will be
made aware through direct outreach from their Shoppers Drug Mart®
pharmacist based on their health profile. Additionally, the first
ever third-party HealthTab™ advertising campaign will actively
market the program publicly in the participating region.
As key milestones are accomplished, this initiative will
continue to advance the Company’s mission of making actionable
health information more accessible for everyone by creating the
world’s leading rapid testing network in pharmacy.
To find a location near you, please visit:
healthtab.com/locations
HealthTab™ Market Fast Facts
- Point-of-Care Testing Market to reach $50.6 Billion USD in 2025
(Source)
- Glucose monitoring (diabetes related) to make up the largest
growth with the sector. (Source)
- Nearly 13.6 Million Canadians expected to diabetic or
prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have
pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed
with heart disease each year, often it’s only after a heart attack
they are diagnosed. (Source)
- There are more that 10,000 pharmacies in Canada, 88,000
pharmacies in the US, nearly 12,000 in the UK.
About HealthTab™ +
RASTR
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19. The HealthTab™ network model is unlike anything
in pharmacy today. It gives knowledgeable and trusted pharmacists a
greater role in primary care delivery, while empowering patients to
take more control of their health. It also reduces costs and
waiting times and provides many potential revenue streams including
equipment leasing & consumables, direct access testing, disease
prevention & management programs, sponsored health programs,
decentralized clinical trials, real world data (RWD) sets, and
third-party app integration through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service
innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™ (a wholly owned subsidiary), its mission is to
make actionable health information more accessible to everyone by
creating the world’s largest network of rapid testing devices in
community pharmacies.
Contact:
Avricore Health
Inc. Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com www.avricorehealth.com
Cautionary Note Regarding Forward-Looking
Statements Information in this press release that involves
Avricore Health's expectations, plans, intentions or strategies
regarding the future are forward-looking statements that are not
facts and involve a number of risks and uncertainties. Avricore
Health generally uses words such as "outlook," "will," "could,"
"would," "might," "remains," "to be," "plans," "believes," "may,"
"expects," "intends," "anticipates," "estimate," "future,"
"positioned," "potential," "project," "remain," "scheduled," "set
to," "subject to," "upcoming," and similar expressions to help
identify forward-looking statements. In this press release,
forward-looking statements include statements regarding: the
completion of the placement and the expected timing thereof and the
Company's expected use of proceeds from the placement; the unique
features that the HealthTab™ platform offers to pharmacists and
patients. Forward-looking statements reflect the then-current
expectations, beliefs, assumptions, estimates and forecasts of
Avricore Health's management. The forward-looking statements in
this press release are based upon information available to Avricore
Health as of the date of this press release. Forward-looking
statements believed to be true when made may ultimately prove to be
incorrect. These statements are not guarantees of the future
performance of Avricore Health and are subject to a number of
risks, uncertainties and other factors, some of which are beyond
its control and may cause actual results to differ materially from
current expectations, including without limitation: failure to meet
regulatory requirements; changes in the market; potential downturns
in economic conditions; and other risk factors described in
Avricore's public filings. These forward-looking statements speak
only as of the date on which they are made, and the Company
undertakes no obligation to update them publicly to reflect new
information or the occurrence of future events or circumstances,
unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024